Aptorum Group Ltd
NASDAQ:APM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aptorum Group Ltd
NASDAQ:APM
|
UK |
|
Soma Textiles & Industries Ltd
NSE:SOMATEX
|
IN |
|
B
|
Banco Pan SA
BOVESPA:BPAN4
|
BR |
|
Darkpulse Inc
OTC:DPLS
|
US |
|
Century Textiles and Industries Ltd
BSE:500040
|
IN |
|
T
|
Tian Teck Land Ltd
HKEX:266
|
HK |
|
C
|
Chinese Universe Publishing and Media Group Co Ltd
SSE:600373
|
CN |
|
Qingdao Eastsoft Communication Technology Co Ltd
SZSE:300183
|
CN |
|
S
|
S&S Tech Corp
KOSDAQ:101490
|
KR |
Aptorum Group Ltd
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.
